Neurovascular regulation in diabetic retinopathy and emerging therapies

Liyang Ji,Hong Tian,Keith A. Webster,Wei Li

DOI: https://doi.org/10.1007/s00018-021-03893-9

IF: 8

2021-07-07

Cellular and Molecular Life Sciences

Abstract:<p class="a-plus-plus">Diabetic retinopathy (DR) is the leading cause of vision loss in working adults in developed countries. The disease traditionally classified as a microvascular complication of diabetes is now widely recognized as a neurovascular disorder resulting from disruption of the retinal neurovascular unit (NVU). The NVU comprising retinal neurons, glia and vascular cells coordinately regulates blood flow, vascular density and permeability to maintain homeostasis. Disturbance of the NVU during DR can lead to vision-threatening clinical manifestations. A limited number of signaling pathways have been identified for intercellular communication within the NVU, including vascular endothelial growth factor (VEGF), the master switch for angiogenesis. VEGF inhibitors are now widely used to treat DR, but their limited efficacy implies that other signaling molecules are involved in the pathogenesis of DR. By applying a novel screening technology called comparative ligandomics, we recently discovered secretogranin III (Scg3) as a unique DR-selective angiogenic and vascular leakage factor with therapeutic potential for DR. This review proposes neuron-derived Scg3 as the first diabetes-selective neurovascular regulator and discusses important features of Scg3 inhibition for next-generation disease-targeted anti-angiogenic therapies of DR. </p>

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the neurovascular regulatory mechanism of diabetic retinopathy (DR) and its emerging therapies. Specifically, the article explores the following issues:

1. **Traditional understanding and modern cognition of DR**:
- Traditionally, DR has been regarded as a microvascular complication of diabetes.
- Modern research believes that DR is a neurovascular disease, and its pathological mechanism involves the destruction of the retinal neurovascular unit (NVU).

2. **Composition and function of NVU**:
- NVU is composed of retinal neurons, glial cells and vascular cells, which jointly regulate blood flow, vascular density and permeability to maintain homeostasis.
- In DR, the disorder of NVU may lead to clinically visible manifestations that threaten vision.

3. **Signal pathways and molecular mechanisms**:
- Some signal pathways for inter - cellular communication within NVU have been identified, such as vascular endothelial growth factor (VEGF), which is a major regulator of angiogenesis.
- Although VEGF inhibitors are widely used in the treatment of DR, their limited efficacy indicates that other signal molecules are also involved in the pathogenesis of DR.

4. **Application of new screening techniques**:
- By applying a new technology called comparative ligandomics, researchers have discovered secretogranin III (Scg3), which is a unique DR - selective angiogenic and vascular leakage factor with therapeutic potential.

5. **Scg3 as a new therapeutic target**:
- It is proposed that Scg3 is the first diabetes - selective neurovascular regulator, and the important features of Scg3 inhibition in the new - generation anti - angiogenic therapies are discussed.

6. **Limitations of existing treatment methods and the prospects of new therapies**:
- Current treatment methods such as laser therapy and VEGF inhibitors have certain limitations and side effects.
- Emerging anti - Scg3 therapies may provide safer and more effective treatment options, especially when targeting severe DR lesion areas.

In summary, this paper aims to reveal the neurovascular regulatory mechanism of DR and explore new treatment methods based on Scg3, in order to improve the treatment effect of DR and reduce side effects.